p values for treatment diﬀ  erence are presented for weeks 8, 14, 18, 22, and 26. 95% CIs for treatment diﬀ  erences were: week 8 (0·27–0·43), week 14 (0·16–0·37),  week 18 (0·09–0·31), week 22 (0·08–0·32), and week 26 (0·08–0·33). HbA 1c=glycated haemaglobin. *p<0·0001. †p=0·0005. ‡p=0·0012. §p=0·0018. Exenatide Liraglutide Treatment diﬀ  erence LS mean (SE) 95% CI LS mean (SE) 95% CI LS mean (SE) 95% CI HbA1c (%) All patients –1·28% (0·05; n=390) –1·38 to –1·18 –1·48% (0·05; n=386) –1·58 to –1·38 0·21% (0·07) 0·08 to 0·33 <9% –1·05% (0·06; n=314) –1·16 to –0·94 –1·20% (0·06; n=308) –1·31 to –1·09 0·15% (0·08) 0·00 to 0·30 ≥9% –1·75% (0·09; n=136) –1·92 to –1·58 –2·04% (0·09; n=136) –2·21 to –1·87 0·29% (0·12) 0·06 to 0·53 Fasting serum glucose (mmol/L) –1·76 (0·11) –1·98 to –1·54 –2·12 (0·12) –2·34 to –1·89 0·36 (0·15) 0·05 to 0·66 Bodyweight (kg) All patients –2·68 (0·18; n=404) –3·03 to –2·32 –3·57 (0·18; n=398) –3·94 to –3·21 0·90 (0·26) 0·39 to 1·40